Home Athersys, Inc. (ATHX) Upgraded to Buy at Zacks Investment Research
 

Keywords :   


Athersys, Inc. (ATHX) Upgraded to Buy at Zacks Investment Research

2016-03-12 01:37:03| Biotech - Topix.net

The brokerage presently has a $2.50 price target on the biopharmaceutical company's stock. Zacks Investment Research 's price objective would indicate a potential upside of 14.68% from the company's current price.

Tags: buy research investment upgraded

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
01.11Atlantic Tropical Weather Outlook
01.11Eastern North Pacific Tropical Weather Outlook
01.11Boeing makes 38% pay rise offer in bid to end strike
01.11The house paints that promise much more than colour
01.11Eastern North Pacific Tropical Weather Outlook
01.11Atlantic Tropical Weather Outlook
01.11Technology adoption: What's on the ag tech horizon for 2025
01.11Technology adoption: What's on the ag tech horizon for 2025
More »